eprintid: 10048256 rev_number: 19 eprint_status: archive userid: 608 dir: disk0/10/04/82/56 datestamp: 2018-05-15 17:07:22 lastmod: 2021-09-25 23:20:15 status_changed: 2018-05-15 17:07:22 type: article metadata_visibility: show creators_name: Rider, LG creators_name: Aggarwal, R creators_name: MacHado, PM creators_name: Hogrel, JY creators_name: Reed, AM creators_name: Christopher-Stine, L creators_name: Ruperto, N title: Update on outcome assessment in myositis ispublished: pub divisions: UCL divisions: B02 divisions: C07 divisions: D07 divisions: F85 note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: The adult and juvenile myositis syndromes, commonly referred to collectively as idiopathic inflammatory myopathies (IIMs), are systemic autoimmune diseases with the hallmarks of muscle weakness and inflammation. Validated, well-standardized measures to assess disease activity, known as core set measures, were developed by international networks of myositis researchers for use in clinical trials. Composite response criteria using weighted changes in the core set measures of disease activity were developed and validated for adult and juvenile patients with dermatomyositis and adult patients with polymyositis, with different thresholds for minimal, moderate and major improvement in adults and juveniles. Additional measures of muscle strength and function are being validated to improve content validity and sensitivity to change. A health-related quality of life measure, which incorporates patient input, is being developed for adult patients with IIM. Disease state criteria, including criteria for inactive disease and remission, are being used as secondary end points in clinical trials. MRI of muscle and immunological biomarkers are promising approaches to discriminate between disease activity and damage and might provide much-needed objective outcome measures. These advances in the assessment of outcomes for myositis treatment, along with collaborations between international networks, should facilitate further development of new therapies for patients with IIM. date: 2018-05-01 date_type: published official_url: http://doi.org/10.1038/nrrheum.2018.33 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green article_type: review verified: verified_manual elements_id: 1555439 doi: 10.1038/nrrheum.2018.33 lyricists_name: Machado, Pedro lyricists_id: PMMAC99 actors_name: Machado, Pedro actors_id: PMMAC99 actors_role: owner full_text_status: public publication: Nature Reviews Rheumatology volume: 14 number: 5 pagerange: 303-318 issn: 1759-4804 citation: Rider, LG; Aggarwal, R; MacHado, PM; Hogrel, JY; Reed, AM; Christopher-Stine, L; Ruperto, N; (2018) Update on outcome assessment in myositis. [Review]. Nature Reviews Rheumatology , 14 (5) pp. 303-318. 10.1038/nrrheum.2018.33 <https://doi.org/10.1038/nrrheum.2018.33>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10048256/1/Myositis%20Outcome%20Assessment%20Nature%20Reviews%20final%20%201-22-18.pdf